A key conclusion of this review article is that TGase 2 is a valid target for ccRCC because TGase 2 is the major regulator of functional p53 in ccRCC, and inhibitors that interfere with binding between TGase 2 and p53 show therapeutic potential. Here, TP53 is linked to nonpapillary renal cell carcinoma.